Replies to post #551 on Vascular Biogenics Ltd (VBLT)

[davidal66]

Having thought about it a bit more, I think was the company is looking at is the potential separation of the KM survival curves in light of an accelerating enrollment rate from August 2015 until the end of December 2016. US Centers came online at different time points after August '15 and, most likely, individual enrollment rates in each center accelerated over time. Israel and Canada came online well after August '15 and so on. So the company is looking at potential separation of the KM survival plots over time... and the 12 months of potential drug time should come after the 105 events.... so the net total events at the interim analysis should actually surpass 105 events.